ADIAL PHARMACEUTICALS, INC. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/91179807-bd06-41fc-8830-6700ae18b5cd/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-7.8M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-024175 |
| FY 2024 | $-8.3M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-019771 |
| FY 2023 | $-6.9M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-028701 |
| FY 2022 | $-10.9M | 2022-01-01 – 2022-12-31 | evidence 0001213900-24-028701 |
| FY 2021 | $-19.3M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-015562 |
| FY 2020 | $-10.9M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-017009 |
| FY 2019 | $-8.2M | 2019-01-01 – 2019-12-31 | evidence 0001213900-20-007020 |
| FY 2018 | $-7.0M | 2018-01-01 – 2018-12-31 | evidence 0001213900-19-002769 |
| FY 2017 | $-995.3k | 2017-01-01 – 2017-12-31 | evidence 0001213900-19-002769 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).